Clinical Trial

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-06-10
Trial Details
NCT Number NCT07140328
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Chronic Obstructive Lung Disease (COLD)
Enrollment 50 participants
Start Date 2025-04-24
Primary Completion 2025-07-10 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-09